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Outcomes of 475 consecutive patients undergoing ﬁrst allogeneic transplantation for hematologic malignancy
performed using T-replete HLA-haploidentical donors and post-transplantation cyclophosphamide (HIDT;
n ¼ 116) were compared with contemporaneous patients transplanted from 10 of 10 HLA allele-matched
unrelated donors (MUDT; n ¼ 178) or HLA-identical sibling donors (MRDT; n ¼ 181). Uniform supportive
care measures and assessments were used. Median follow-up was 45 months. HIDT patients were more likely
than MUDT patients to be black (44% versus 2%; P < .001). At 2 years after transplantation, estimates of overall
survival were 57% for HIDT, 59% for MUDT, and 72% for MRDT (P not signiﬁcant [NS] for HIDT versus MUDT;
P ¼ .02 for HIDT versus MRDT); corresponding disease-free survival rates were 54%, 50%, and 56% (P NS for
both comparisons). The respective cumulative incidences (CIs) of nonrelapse mortality were 17%, 16%, 14%,
and those of relapse were 29%, 34%, and 30% (P NS for all). The respective CIs of acute graft-versus-host
disease (GVHD) grade II-IV were 41%, 48%, and 28% (P ¼ NS for HIDT versus MUDT; P ¼ .005 for HIDT
versus MRDT). At 2 years, the respective CIs of moderate/severe chronic GVHD were 31%, 47%, and 44% (P ¼
.004 for HIDT versus MUDT; P ¼ .032 for HIDT versus MRDT) and 19% of HIDT recipients, 42% of MUDT
recipients, and 35% of MRDT recipients were on systemic immunosuppressive treatment (P ¼ .007 for HIDT
versus MUDT). In recipients of peripheral blood stem cell grafts, the incidence of moderate-severe chronic
GVHD was signiﬁcantly lower in HIDT recipients compared with MUDT recipients (2-year CI, 25% versus 48%;
P ¼ .002). In a multivariate analysis incorporating Disease Risk Index and other signiﬁcant covariates, survival
(hazard ratio [HR], 1.31; P ¼ .15) and disease-free survival (HR, 0.96; P ¼ .79) were not signiﬁcantly different
between HIDT and MUDT recipients, but the incidence of chronic GVHD was lower in HIDT recipients
(moderate-severe, HR, 0.59; P ¼ .007). HIDT produced similar long-term survival with lower rates of chronic
GVHD than optimally matched MUDT. HIDT should be considered a standard of care option for patients
lacking a matched sibling donor.
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ty for Blood and Marrow Transplantation.for control of alloreactivity (HIDT) has emerged as an important
option for patients who lack a conventional HLA-matched sib-
ling or unrelated donor for allogeneic hematopoietic trans-
plantation [1-7]. Unlike previous attempts at haploidentical
donor transplantation that relied on stringent ex vivo T cell
depletion, HIDT is associated with low rates of nonrelapse
mortality (NRM) and robust early immune reconstitution [8].
The promising early results of HIDT has invited comparisons of
A. Bashey et al. / Biol Blood Marrow Transplant 22 (2016) 125e133126these transplantations with those performed using HLA-
identical sibling donors (MRDT) and those performed using
HLA-matchedunrelateddonors (MUDT)donors.Noprospective
randomized comparison of transplantations using these donor
sources has been reported. Early retrospective comparisons
have suggested encouraging outcomes forHIDTcomparedwith
MRDT and MUDT [5,9,10]; however, such comparisons have
been limited by small numbers, short follow-up times, and
potential bias attributable to patient selection. In particular,
imbalances in risk status of malignancies among the 3 groups
may obfuscate the effect of donor type.
Until recently, no satisfactory measure of disease risk has
been available for comparing relapse risk across different
hematologic malignancies in patients undergoing allogeneic
hematopoietic transplantation. The Dana-Farber/Center for
International Blood and Marrow Transplant Research
(CIBMTR) Disease Risk Index (DRI) was recently developed to
address this need [11,12]. More than 13,000 patients who
underwent hematopoietic cell transplantation between
2008 and 2010 were used to develop the 4-group DRI with
2-year survivals ranging from 64% to 24%. The DRI was sub-
sequently reﬁned and validated, and provides a robust tool
for adjusting outcomes in retrospective comparisons for
imbalances in disease type and status. In the present anal-
ysis, we used the DRI and other signiﬁcant covariates to
compare outcomes of HIDT, MRDT, and MUDT in 475
consecutive patients contemporaneously undergoing ﬁrst
allogeneic stem cell transplantation for hematologic malig-
nancy at our center using standardized supportive care al-
gorithms and assessments with a median follow-up of nearly
4 years.
PATIENTS AND METHODS
Patients
The present study included 475 patients who underwent ﬁrst allogeneic
transplantation for hematologic malignancy at our center using an HLA-
identical sibling donor (MRD; n ¼ 181), a 10 of 10 HLA-A, -B, -C, -DRB1,
and -DQB1 allele-matched volunteer unrelated donor (MUDT; n ¼ 178), or T
cellereplete haploidentical graft using post-transplantation cyclophospha-
mide (HIDT; n ¼ 116). The transplantations were performed consecutively
between February 2005 and February 2014. This time frame was chosen to
start at the date on which the ﬁrst HIDTs were performed through to the
present and to allow a minimum of 12 months of post-transplantation
follow-up for surviving patients. At our center, HIDT was used if no suit-
able donor for MRDT or 10 of 10 HLA allele-matched MUDT was available
within an acceptable time frame. Nine of 10 HLA allele-matched donors for
MUDT were prioritized over HIDT until 2013; since then, HIDT has been
prioritized over 9 of 10 HLA allele-matched MUDT. Eighty-three patients
who underwent allogeneic transplantation at our center during this period
were excluded from this analysis. Causes for exclusion were second allo-
transplant (40 patients), <10 of 10 allele-matched MUD (23 patients), cord
blood transplantation (11 patients), and allogeneic transplantation for
nonmalignant disease (9 patients).
Conditioning Regimens
The patients received pretransplantation conditioning using various
preparative regimens, classiﬁed as myeloablative (MAC), reduced-intensity
(RICT), and nonmyeloablative (NST) according to accepted criteria [13,14].
All patients were managed similarly in the outpatient setting, with inpatient
admission reserved for complications and symptoms that could not be
managed on an outpatient basis. Supportive care algorithms, post-
transplantation follow-up, and assessments were identical in the 3 groups.
HIDT
All nonmyeloablative HIDTs (n ¼ 70) were performed following the
regimen published by Johns Hopkins University [2], consisting of ﬂudar-
abine 30 mg/m2 i.v. once daily on days 6 to2, total-body irradiation (TBI)
2 Gy on day1, and cyclophosphamide 14.5 mg/kg i.v. once daily on days6
and 5 and 50 mg/kg once daily on days þ3 and þ4 when using a PBSC or
bone marrow graft. Myeloablative HIDTs (n ¼ 46) were performed using 2regimens developed at our institution [15,16]. Twenty-one patients received
regimen 1: ﬂudarabine 25 mg/m2 i.v. once daily on days 6 to 2, busulfan
110 to 130 mg/m2 i.v. once daily on days 7 to 4, and cyclophosphamide
14.5 mg/kg i.v. once daily on days 3 and 2 and 50 mg/kg once daily on
days þ3 and þ4. Twenty-ﬁve patients received regimen 2: ﬂudarabine 30
mg/m2 once daily on days 7 to 5, TBI 150 cGy twice daily on days 4
to 1 (total dose 1200 cGy), and the same post-transplantation therapy as
for regimen 1. Granulocyte colony-stimulating factoremobilized PBSCs
(dose capped at 5  106 CD34þ cells/kg) served as the graft source for all
myeloablative HIDTs.
MUDT and MRDT
HLA-matched transplants were performed using standard regimens at
our institution that were classiﬁed as MAC, RIC, or NST using accepted
criteria [13,14]. The regimens used included busulfan/cyclophosphamide
(n ¼ 91), fudarabine/busulfan (n ¼ 46), ﬂudarbine/busulfan/cyclophospha-
mide (n ¼ 53), ﬂudarabine/melphalan (n ¼ 39), etoposide/TBI (n ¼ 36),
ﬂudarabine/cyclophosphamide (n ¼ 28), ﬂudarbine/cyclophosphamide/TBI
(n ¼ 27), cyclophosphamide/TBI (n ¼ 16), busulfan/cyclophosphamide/
etoposide (n¼ 11), melphalan/TBI (n¼ 4), ﬂudarbine/TBI (n¼ 4), and others
(n ¼ 4). Tacrolimus and methotrexate was the standard GVHD prophylaxis.
Twenty-six MRDT recipients and 10 MUDT recipients received rabbit
antithymocyte globulin as part of their conditioning, and 9 MRDT recipients
and 39 MUDT recipients received alemtuzumab. No patient received an
ex vivo T celledepleted graft.
Covariates
Patient-, disease-, and transplant-related variables were documented
prospectively and obtained for this analysis from our comprehensive insti-
tutional database. The DRI was assigned retrospectively to each patient
using the criteria published by Armand et al [12].
Endpoints
Primary outcomes analyzed were overall survival (OS), disease-free
survival (DFS, deﬁned as survival without evidence of active malignancy
after transplantation), NRM, relapse/progression of malignancy, and acute
and chronic graft-versus-host disease (GVHD). Acute GVHD was graded
based on the modiﬁed Keystone criteria [17] and subclassiﬁed as clinically
signiﬁcant (grade II-IV) or severe (grade III-IV). Because of the possibility of
delayed onset of clinical acute GVHD after transplantation performed using
RICT/NST regimens, the maximum cumulative incidence (CI) of acute GVHD
was assessed at 6months after transplantation. Chronic GVHDwas classiﬁed
as mild, moderate, or severe by National Institutes of Health consensus
criteria [18]. Acute and chronic GVHD were prospectively evaluated, graded,
and documented by a single dedicated and specialized practitioner.
Statistical Analysis
Patient characteristics were compared using the Kruksall-Wallis test for
continuous variables and the chi-squared test for categorical variables. OS
and DFS were estimated by the Kaplan-Meier method. CIs of NRM, relapse,
and GVHD were calculated to accommodate competing risks.
Comparison of outcomes in the 3 donor types was conducted at a ﬁxed
time point, 6 months for acute GVHD and 2 years for all other endpoints
using the Wald test. Fisher’s exact test was used to compare the use of
systemic immunosuppressive therapy at 2 years post-transplantation for
surviving patients. Global tests were also conducted to compare outcomes
for the 3 donor types over the entire study period. Global comparisons of OS
and DFS were evaluated using the log-rank test. Gray’s test was used to
compare CIs. Comparisons of HIDT versus MUDT and HIDT versus MRDT
were of study interest. The P values associated with these 2 comparisons
were corrected by the Bonferroni method. In multivariate analysis, the Cox
models and the logistic regression model were built by testing the following
covariates: donor type (MRDT, MUDT, or HIDT), patient age (65 and 55-64
versus <55 years), DRI (very high or high versus low/intermediate risk),
Hematopoietic Cell Transplant Comorbidity Index (HCT-CI; 3 versus 2),
diagnosis (acute myelogenous leukemia [AML] versus other), regimen
(ablative versus RIC/nonmyeloablative), year of transplantation (2012
versus earlier), graft source (bone marrow versus PBSCs), cytomegalovirus
serostatus (both positive, donor positive and recipient-negative, donor-
negative and recipient-positive versus both negative), ABO match
(compatible, minor incompatible versus major incompatible) and donor age
(50, 30-50 versus<30 years). The Coxmodels always kept donor type even
if its coefﬁcients were not signiﬁcant. Other covariates were selected by the
backward elimination method and were held in the Cox models if the P
value was <.05. Statistical analysis was performed using the SAS version 9.3
(SAS Institute, Cary, NC) and the R package cmprsk.
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Patient Characteristics
Donor selection was based on an institutional algorithm
that prioritized HLA-identical sibling donors, followed by
optimally matched unrelated donors. Patients lacking such
donors were offered HIDT if an HLA-haploidentical donor
was available without clinically signiﬁcant donor-speciﬁc
antibodies in the patient serum. Characteristics of the
study patients are described in Table 1. HIDT recipients
were matched at a median of 5 of 10 HLA-A, -B, -C, -DRB1,
and -DQB1 alleles (range, 5-8 alleles), whereas all MUDTTable 1
Patient Characteristics
MRDT
Number 181
Age, yr, median (range) 52 (18-77)
Female sex, n (%) 76 (42)
Race
White 147 (81)
Black 29 (16)
Asian 5 (3)
Regimen, n (%)
Ablative 97 (54)
NST/RIC 84 (46)
Diagnosis, n (%)
ALL 18 (10)
AML 61 (34)
CLL 6 (3)
CML 8 (4)
HL 13 (7)
MDS 23 (13)
MM 10 (6)
MPS 10 (6)
NHL 32 (17)
Previous autologous transplantation, n (%)
No 148 (82)
Yes 33 (18)
Graft source, n (%)
Bone marrow 2 (1)
PBSCs 179 (99)
DRI, n (%)
Low 23 (13)
Intermediate 85 (48)
High 58 (32)
Very high 13 (7)
DRI, n (%)
Low/intermediate 108 (60)
High/very high 71 (40)
CMI score, n (%)
0 46 (26)
1-2 71 (39)
3 64 (35)
Donor age, yr, n (%)
<30 7 (4)
30-50 49 (27)
50 125 (69)
ABO matching, n (%)
Compatible 113 (63)
Minor incompatible 28 (16)
Major incompatible 38 (21)
CMV status, n (%)
Donor/recipient 38 (21)
Donor/recipientþ 43 (24)
Donorþ/recipient 21 (11)
Donorþ/recipientþ 79 (44)
Year of transplantation, n (%)
2005-2008 81 (45)
2009-2011 54 (30)
2012-2014 46 (25)
Time from diagnosis to transplantation, d, median 227
ALL indicates acute lymphoblastic leulemia; CLL, chronic lymphocytic leukemia; CM
syndrome; MM, multiple myeloma; MPS, myeloproliferative syndrome; NHL, non
morbidity Index; ABO, blood group; CMV, cytomegalovirus.recipients were matched at 10 of 10 alleles and all MRDT
recipients were HLA-identical. HIDT patients were more
likely to be black, to have received a bone marrow graft, and
to have undergone transplantation after 2008. Donor age
was younger for MUDT recipients. Age, sex, DRI, previous
autografts, and HCT-CI scores were not signiﬁcantly different
among the 3 groups. A total of 149 patients (31%), including
73 HIDT recipients, 23 MUDT recipients, and 53 MRDT re-
cipients, were treated on a clinical trial protocol. The median
follow-up for survivors was 45 months (range, 13-120
months).MUDT HIDT P Value
178 116
53 (19-74) 51 (20-74) .249
83 (47) 53 (46) .643
<.001
172 (96) 64 (55)
3 (2) 51 (44)
3 (2) 1 (1)
.052
91 (51) 46 (40)
87 (49) 70 (60)
.046
28 (16) 16 (14)
70 (39) 39 (34)
7 (4) 13 (11)
11 (6) 10 (9)
5 (3) 11 (9)
21 (12) 9 (8)
3 (2) 2 (2)
7 (4) 4 (3)
26 (14) 12 (10)
.170
158 (89) 100 (86)
20 (11) 16 (14)
<.001
32 (18) 64 (55)
146 (82) 52 (45)
.051
27 (15) 23 (20)
96 (54) 46 (40)
38 (22) 41 (35)
16 (9) 6 (5)
.114
123 (69) 69 (59)
54 (31) 47 (41)
.877
52 (29) 32 (28)
66 (37) 48 (41)
60 (34) 36 (31)
<.001
101 (60) 24 (21)
65 (38) 54 (46)
4 (2) 38 (33)
<.001
66 (38) 65 (57)
62 (36) 31 (27)
45 (26) 18 (16)
<.001
56 (31) 20 (17)
54 (30) 26 (22)
24 (14) 11 (10)
44 (25) 59 (51)
<.001
53 (30) 14 (12)
58 (33) 58 (50)
67 (38) 44 (38)
216 484 .002
L, chronic myeloid leukemia; HL, Hodgkin lymphoma; MDS, myelodysplastic
-Hodgkin lymphoma; PBSC, peripheral blood stem cellls; CMI, Sorror Co-
Table 2
Multivariate Cox Models with Donor Type as Covariate
Factor Level HR 95% CI P Value
Cox model on OS
Donor type MUDT
MRDT 0.42 0.27-0.67 <.001
HIDT 1.04 0.68-1.59 .859
DRI Low/intermediate
High/very high 2.18 1.65-2.88 <.001
Race and sex White female
White male 1.21 0.89-1.64 .214
Black female 0.33 0.16-0.69 .003
Black male 1.08 0.63-1.87 .772
Age <55 yr
55-64 yr 1.45 1.06-1.97 .020
65 yr 1.89 1.27-2.82 .002
CMI 0-2
3 1.35 1.01-1.81 .043
Donor age <30 yr
30-50 yr 1.17 0.80-1.72 .424
50 yr 1.92 1.19-3.10 .007
Cox model on DFS
Donor type MUDT
MRDT 0.72 0.54-0.96 .027
HIDT 0.96 0.69-1.32 .788
DRI Low/intermediate
High/very high 2.28 1.77-2.94 <.001
Sex Female
Male 1.38 1.06-1.78 .015
Age <55 yr
55-64 yr 1.61 1.22-2.13 <.001
65 yr 2.10 1.45-3.06 <.001
Year of transplantation 2005-2011
2012-2014 0.68 0.50-0.91 .010
Cox model on NRM
Donor type MUDT
MRDT 0.86 0.53-1.40 .549
HIDT 1.27 0.74-2.18 .396
Diagnosis Non-AML
AML 0.57 0.35-0.93 .026
Regimen Myeloablative
NST/RIC 0.63 0.40-0.99 .049
Age <55 yr
55-64 yr 2.23 1.40-3.56 <.001
65 yr 2.68 1.34-5.34 .005
CMI 0-2
3 1.69 1.09-2.60 .018
Cox model on relapse
Donor type MUDT
MRDT 0.68 0.47-0.97 .034
HIDT 0.86 0.57-1.28 .452
DRI Low/intermediate
High/very high 2.86 2.09-3.93 <.001
Age <55 yr
55-64 yr 1.32 0.92-1.89 .130
65 yr 2.04 1.29-3.23 .002
Year of transplantation 2005-2011
2012-2014 0.57 0.39-0.84 .004
Cox model on grade II-IV acute GVHD
Donor type MUDT
MRDT 0.51 0.36-0.71 <.001
HIDT 0.77 0.54-1.09 .134
Year of transplantation 2005-2011
2012-2014 1.45 1.08-1.94 .012
Cox model on grade III-IV acute GVHD
Donor type MUDT
MRDT 0.47 0.26-0.84 .012
HIDT 0.99 0.58-1.71 .985
Cox model on moderate-severe chronic GVHD
Donor type MUDT
MRDT 0.83 0.61-1.12 .217
HIDT 0.59 0.40-0.87 .007
Year of transplantation 2005-2011
2012-2014 0.62 0.45-0.84 .003
Cox model on severe chronic GVHD
Donor type MUDT
MRDT 0.90 0.56-1.46 .677
HIDT 0.37 0.17-0.80 .012
(Continued on next page)
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Table 2
(continued)
Factor Level HR 95% CI P Value
Logistic regression model on systemic immunosuppressive therapy at 2 years
Donor type MUDT
MRDT 0.58 0.30-1.11 .024
HIDT 0.19 0.07-0.50 <.001
Race White
Black 2.34 1.03-5.34 .043
Sex Female
Male 2.28 1.27-4.10 .006
Age <55 yr
55-64 yr 0.49 0.24-0.99 .049
65 yr 2.34 0.86-6.32 .094
Cox model on time to ANC 500/mm3
Donor type MUDT
MRDT 0.86 0.69-1.06 .156
HIDT 0.50 0.39-0.65 <.001
Race White
Black 1.31 1.01-1.69 .044
Year of transplantation 2005-2011
2012-2014 0.71 0.58-0.87 <.001
Cox model on time to platelets 20,000/mm3
Donor type MUDT
MRDT 1.28 1.03-1.58 .024
HIDT 0.58 0.45-0.73 <.001
CMI 0-2
3 0.75 0.62-0.92 .005
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Engraftment failure occurred in 3 (2.6%) HIDT recipients,
3 (1.7%) MUDT recipients, and 3 (1.7%) MRDT recipients (P ¼
NS). There were no cases of engraftment failure in HIDT
recipients who received myeloablative conditioning. The
median time to an absolute neutrophil count (ANC) 500/
mm3 were 16 days for HIDT, 14 days for MUDT, and 14 days
for MRDT (P < .001 HIDT, versus MUDT and HIDT versus
MRDT). The corresponding median time to a platelet count
20,000/mm3 was 26 days, 19 days, and 18 days (P < .001
HIDT versus MUDT and HIDT versus MRDT). Neutrophil and
platelet recovery was not signiﬁcantly different between
HIDT patients who received a PBSC graft (median time to
ANC 500/mm3, 16 days; median time to platelet count
20,000/mm3, 26 days) and HIDT patients who received a
bone marrow graft (16 days and 25 days, respectively). In a
multivariable Cox analysis, HIDT was associated with
signiﬁcantly longer times to neutrophil and platelet recov-
ery (Table 2).
GVHD
CIs of acute GVHD grade II-IV and grade III-IV are shown
in Figure 1A and B. The CIs of acute GVHD at 6 months were
41% for HIDT, 48% for MUDT, and 21% MRDT for grade II-IV
(P ¼ NS for HIDT versus MUD and P ¼ .005 for HIDT
versus MRD on pointwise comparison) and 17%, 18% and 9%,
respectively, for grade III-IV (P ¼ NS for HIDT versus MUDT
and P ¼ .054 HIDT versus MRDT). On global comparison, the
CIs of acute GVHD were not signiﬁcantly different between
HIDT and MUDT, whereas HIDT was associated with
signiﬁcantly higher incidence of acute GVHD compared
with MRDT (P ¼ .048 for grade II-IV and P ¼ .039 for grade
III-IV).
CIs of moderate-severe chronic GVHD and severe
chronic GVHD are shown in Figure 1C and D. The 2-year CI
of moderate-severe chronic GVHD was signiﬁcantly lower
in HIDT recipients than in MUDT or MRDT recipients (31%
versus 47% versus 44%; P ¼ .004 for HIDT versus MUDT andP ¼ .032 for HIDT versus MRDT on pointwise comparison).
The 2-year CI of severe GVHD was 7% for HIDT, 15% for
MUDT, and 14% for MRDT (P ¼ .06 for HIDT versus MUDT
and P ¼ .08 for HIDT versus MRDT on pointwise compari-
son). On global comparison, P values for moderate-severe
chronic GVHD were 0.015 for HIDT versus MUDT and
0.045 for HIDT versus MRDT, and P values for severe
chronic GVHD were .013 for HIDT versus MUDT and .014
for HIDT versus MRDT.
To avoid the potential confounding effect of the greater
use of bone marrow versus PBSCs in the HIDT recipients, the
CI of moderate-severe chronic GVHD was also determined
for patients receiving PBSC grafts only (n ¼ 377, including 52
HIDT, 146 MUDT, and 179 MRDT) (Figure 1E). The 2-year CIs
of moderate-severe chronic GVHD for 25% for HIDT, 48% for
MUDT, and 45% for MRDT (P¼ .002 for HIDT versus MUD and
P ¼ .01 for HIDT versus MRDT).
On multivariate Cox regression analysis, the risk of acute
GVHD was not signiﬁcantly different between MUDT and
HIDT (grade II-IV, hazard ratio [HR], 0.77, P¼ .134; grade II-IV,
HR, 0.99, P ¼ .985) (Table 2). However, the risk of chronic
GVHD was signiﬁcantly lower in HIDT compared with MUDT
(moderate-severe, HR, 0.59, P ¼ .007; severe, HR, 0.37,
P ¼ .012).
To further assess the clinical impact of chronic GVHD on
patients undergoing transplantation using the 3 donor
types, we also assessed the requirement for continued
systemic immunosuppression. For patients alive at 1 year
post-transplantation (n ¼ 365), 43% of HIDT recipients (n ¼
83), 64% of MUDT recipients (n ¼ 135), and 55% of MRDT
recipients (n ¼ 147) remained on systemic immunosup-
pressive therapy (P ¼ .006 for HIDT versus MUDT, P ¼ NS for
HIDT versus MRDT). For patients alive at 2 years (n ¼ 255),
19% of HIDT recipients (n ¼ 59), 42% of MUDT recipients
(n ¼ 81), and 35% of MRDT recipients (n ¼ 115) remained
on systemic immunosuppressive therapy (P ¼ .007 for
HIDT versus MUDT, P ¼ .069 for HIDT versus MRDT). On
multivariable logistic regression analysis (Table 2), HIDT
Figure 1. CI of GVHD. (A) Acute GVHD grade II-IV. (B) Acute GVHD grade III-IV. (C) Chronic GVHD grade moderate-severe. (D) Chronic GVHD grade severe. (E) Chronic
GVHD grade moderate-severe for patients receiving a PBSC graft.
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immunosuppressive therapy at 2 years (odds ratio, 0.19
compared with MUDT; P < .001).NRM and Relapse
CIs of NRM and relapse are shown in Figure 2A and B.
There were no signiﬁcant differences in the incidence of
NRM among the 3 donor types. The CIs of NRM at 2 years
were 17% for HIDT, 16% for MUDT, and 14% for MRDT (P ¼ NS
on pointwise and global comparisons). The CIs of relapse at 2
years were 29%, 34%, and 30%, respectively (P ¼ NS on
pointwise and global comparisons).On multivariate Cox regression analysis, the incidences of
NRM (HR, 1.27; P ¼ .396) and relapse (HR, 0.86; P ¼ .452)
were not signiﬁcantly different between MUDT and HIDT.
OS and DFS
Kaplan-Meier estimates of OS and DFS by donor type are
shown in Figure 3A and B. The estimated OS rates at 2 years
were 57% for HIDT, 59% for MUDT, and 72% for MRDT (P ¼ NS
for HIDT versus MUDT and P ¼ .02 for HIDT versus MRDT on
pointwise comparison and P ¼ NS and .017, respectively, on
global comparison). On multivariate Cox regression analysis,
OS was not signiﬁcantly different between MUDT and HIDT
recipients (HR, 1.04; P ¼ .859).
Figure 2. CIs of NRM (A) and relapse/progression (B).
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MUDT, and 56% for MRDT (P ¼ NS for HIDT versus MUDT and
HIDT versus MRDT on pointwise comparison and P ¼ NS for
both on global comparison). On multivariate Cox regression
analysis, DFS was not signiﬁcantly different between MUDT
and HIDT (HR, 0.96; P ¼ .788).
DISCUSSION
This analysis has assessed the outcomes of HIDT
performed using T cellereplete grafts and post-
transplantation cyclophosphamide compared with fully
(10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 alleles) matched
MUDT and MRDT performed contemporaneously at a sin-
gle center with mature follow-up (median follow-up, 45
months; minimum, 13 months). This study is subject to the
caveats typically associated with retrospective analyses.
Speciﬁcally, there was heterogeneity in the conditioning
regimens used, although the time period was selected to
span the ﬁrst HIDT up to the present while allowing for
adequate follow-up. In addition, more HIDTs were per-
formed in later years, and although we attempted to select
donors for the patients using an institutional algorithm,
selection bias nevertheless might have affected donor
choice.
This study also has some strengths. The patients were
managed using identical supportive care measures andFigure 3. Kaplan-Meier estimatpretransplantation and post-transplantation assessments.
Patient characteristics and outcomes were uniformly and
prospectively documented in our institutional database.
Acute and chronic GVHD were assessed and documented
prospectively by an institutionally trained and dedicated
professional for all patients. As such, this analysis may have
less potential for bias based on observer and center differ-
ences compared with analyses obtained retrospectively from
multi-institutional registries. A multivariate analysis was
performed for each endpoint to adjust for confounding pa-
tient-, disease-, and transplant-related variables. Notably, the
newly developed and validated DRI [12] was used to adjust
for potentially signiﬁcant contributions of underlying disease
risk to the outcomes seen. The DRI provides a more precise
way to delineate the risk posed by the status and subtype of
the patient’s malignancy; for example, cytogenetic data are
incorporated into assessment of patients with AML under-
going transplantation in ﬁrst complete remission, and was
missing from most previous comparisons of these 3 donor
types.
The HIDT group contained a much higher proportion of
black patients than the MUDT group (44% versus 2%; P <
.001). This reﬂects our institutional donor selection algo-
rithm and the recognized difﬁculty in obtaining an optimally
matched unrelated donor for black patients [19]. Given the
comparative safety and efﬁcacy of HIDT in our study, thises of OS (A) and DFS (B).
A. Bashey et al. / Biol Blood Marrow Transplant 22 (2016) 125e133132approach has the potential to signiﬁcantly expand access to
allogeneic transplantation for black patients. Compared with
MUDT and MRDT recipients, HIDT recipients had a slightly
longer time to neutrophil recovery and a longer time to
platelet recovery. Although this may reﬂect the greater use of
bone marrow grafts for HIDT, we previously demonstrated
similar times to neutrophil and platelet engraftment
following HIDT in studies from our center that were
restricted to patients receiving PBSC grafts [15,16]. Further-
more, in the present study therewas no signiﬁcant difference
in time to hematopoietic recovery between HIDT patients
receiving PBSCs and those receiving bone marrow grafts.
These ﬁndings suggest that myelosuppression from post-
transplantation cyclophosphamide, rather than the greater
use of bone marrow grafts, is the predominant cause of the
delayed hematopoietic recovery seen in HIDT recipients
compared with MUDT and MRDT recipients in this study.
Our results show that OS, DFS, NRM, and relapse
rates were not signiﬁcantly different between HIDT re-
cipients (median, 5 of 10 HLA allele-mismatched) and 10 of
10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched MUDT
recipients. An optimally (at least 8 of 8 HLA-A, -B, -C, -DRB1)
matched MUDT is considered the standard alternative in
patients who do not have access to MRDT [20]. Our data
provide evidence that HIDT performed following the
approach described here is a suitable alternative in patients
without an optimally matched volunteer unrelated donor
available within an acceptable time frame. Furthermore,
HIDTmay be a better alternative than transplantation using a
suboptimally matched (7 of 8 HLA allele-matched) unre-
lated donor, given that the latter has been demonstrated to
result in inferior outcomes compared with MUDT from an
optimally matched unrelated donor [20,21].
These results help conﬁrm a previous analysis from our
center with much shorter follow-up and a smaller number of
patients performed without adjustment for DRI [5]. In
addition, in the present study, HIDT was compared with
optimally matched unrelated donors only, whereas the pre-
vious analysis included 7 of 8 matched MUDTs. These data
also support smaller analyses from other centers and a
retrospective analysis performed by the CIBMTR restricted to
patients with AML that compared HIDT using this approach
with MUDT by registries and other centers [10,22,23]. Data
from multiple sources suggest that HIDT performed using T
cellereplete grafts and post-transplantation cyclophospha-
mide do not result in inferior outcomes to those seen with
MUDT. In our analysis, MRDT had a superior OS to HIDT;
however, the rates of DFS, NRM, and relapse did not differ. As
we have reported previously, this difference in OS was
largely attributable to superior postrelapse survival (PRS) in
the MRDT recipients (1-year PRS, 59% in MRDT versus 8% in
HIDT; P < .001). The exact reason for this is unclear; less
frequent use of donor lymphocyte infusion following relapse
in HIDT recipients (in 1 of 38, compared with 6 of 57 MRDT
recipients and 6 of 64 MUDT recipients) may have
contributed.
The CIs of grade II-IV and grade III-IV acute GVHD were
not signiﬁcantly different between HIDT and MUDT
recipients; however, the CIs of both moderate-severe and
severe chronic GVHD were signiﬁcantly lower in the HIDT
recipients. Although previous studies have suggested that
HIDT using T cellereplete grafts and post-transplantation
cyclophosphamide are associated with lower rates of
chronic GVHD compared with transplants from conventional
donors [5,10,23], the greater use of bone marrow grafts inHIDT than in conventional donor transplants may confound
such comparisons. Indeed, in the CIBMTR study, when the
comparison was restricted to patients receiving bone
marrow grafts only, no difference in the CI of chronic GVHD
was observed between HIDT recipients and 8 of 8 HLAA-
allele matched MUDT recipients [22]; however, when the
comparison was restricted to patients receiving only PBSC
grafts, the incidence of moderate-severe chronic GVHD was
signiﬁcantly lower in HIDT recipients.
Taken together, the foregoing data imply that although
optimally matched MUDT can have similar rates of chronic
GVHD as HIDT when bone marrow grafts are used, HIDT is
associated with a signiﬁcantly lower incidence of clinically
signiﬁcant chronic GVHD in the setting of PBSC grafts.
Furthermore, our ﬁndings show that the lower rates of
chronic GVHD in HIDT result in signiﬁcantly less need for
systemic immunosuppressive therapy at 1 year and 2 years
post-transplantation. If these data are conﬁrmed in a ran-
domized trial, HIDT may potentially be preferable to MUDT
even in patients where an optimally matched unrelated
donor is available if avoidance of symptomatic chronic GVHD
is a priority. This especially the case given that relapse rates
were no higher for HIDT than for MUDT.
The use of HIDT instead of MUDTmay allow patients with
a precarious remission to proceed more rapidly to trans-
plantation, avoiding the time needed to complete a formal
unrelated donor search and arrange for graft collection at a
remote center. Nonetheless, in our analysis HIDT was not
associated with a shorter time to transplantation (median
time from initial consult to transplantation, 183 days for
HIDT, 152 days for MUDT, and 148 days for MRDT; P ¼ .09 for
HIDT versus MUDT, P ¼ .009 for HIDT versus MRDT). This
may be because our algorithm required demonstration of the
lack of an optimally matched unrelated donor before pro-
ceeding to HIDT. An alternative algorithm that prioritizes
HIDT over MUDT in patients lacking an HLA-identical sibling
may produce much shorter times from initial consult to
transplantation. Similarly, the time from diagnosis to trans-
plantation was signiﬁcantly longer for HIDT compared with
MRDT and MUDT (Table 1), which might have negatively
affected the outcomes of HIDT in our analysis.
Whether HIDT can result in a more rapid progress to
transplantation thanMUDT if the latter is not prioritized, and
whether there are any potential cost savings with HIDT
compared with MUDT, can best be assessed within the
context of a randomized prospective clinical trial of HIDT
versus MUDT in patients lacking an HLA-identical sibling
donor. Such a trial also would be important to conﬁrm the
equivalence in survival outcomes and lower incidence of
chronic GVHD demonstrated for HIDT versus MUDT in our
analysis.
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